Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Cyclacel Pharma (CYCC) Misses Q4 EPS by 83c
February 25, 2021 5:19 PM ESTCyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($1.34), $0.83 worse than the analyst estimate of ($0.51).
During 2020 we have reported on fadraciclibs oral bioavailability and evidence of durable anticancer activity, said Spiro Rombotis, President and Chief Executive Officer. Independent evidence supporting the rationale for... More
